Glaucoma Research & CBD
Glaucoma is a common eye condition that often causes optical nerve damage, and when left untreated, can lead to blindness. In the U.S., more than three million Americans live with glaucoma. Globally, the figure is close to 60 million. Glaucoma is recognized as one of the leading causes of irreversible blindness.
Since 1980, surgical procedures and treatments have improved significantly, cutting the risk of developing blindness nearly in half. Nonetheless, while treatment has improved, the number of effective topical drugs remains limited. Recognized near universally in medical marijuana states as a qualifying condition, increasing numbers of people have turned to cannabis to treat their condition. But should they?
Given the improvement of existing glaucoma treatments, do the benefits of medical cannabis outweigh the potential side effects or risks? Likewise, given the vital role the body’s endocannabinoid system plays in disease, what promise does the future hold for developing cannabinoid-derived medications to treat cannabis?
What Causes Glaucoma?
Evidence increasingly suggests glaucoma (now widely considered to be a neurodegenerative condition), has a connection to other neurodegenerative diseases like Alzheimer’s disease. Studies have shown one out of four Alzheimer’s patients also likely has a diagnosis of glaucoma. In fact, glaucoma appears to be a significant predictor of AD. A precise cause of glaucoma, however, remains a mystery and continues to elude the scientific community.
Can Cannabis be Used for Glaucoma Treatment?
Going back to the 1970s, studies have shown that cannabinoids can alleviate glaucoma-related symptoms because they lower the intraocular pressure (IOP) and have neuroprotective actions. For example, in 1971, one of the first studies of its kind found ingestion of cannabis lowers IOP by 25 to 30 percent.
Despite the findings from early research, very few ophthalmologists support the use of medical marijuana in patients with early to mid-stage glaucoma. The main issue ophthalmologists have with cannabis is that the potential adverse effects — particularly smoking cannabis — outweigh the short term benefits. For example, smoking can lead to unstable intraocular pressure, thereby increasing risk of permanent vision loss.
Further, because its therapeutic effects on glaucoma are short-term, patients would have to consume cannabis frequently — once every three to four hours. Doctors claim that because glaucoma needs to be treated 24 hours per day, patients would need to consume cannabis six to eight times over the course of a day to achieve consistently lowered IOP levels. Such frequency is hard to maintain and could increase the risk of developing a cannabis use disorder.
However, when it comes to late stage glaucoma, ophthalmologists are more inclined to embrace cannabis as a treatment. At the end stages of glaucoma, it’s less about directly targeting the glaucoma and more about alleviating the accompanying symptoms.
According to ophthalmologist Andrew Bainnson, MD, “We’ve known for some time that medical marijuana is very effective for treating nausea and pain, but not so much for glaucoma,” said Bainnson. “[However,] there are some patients with end stage pain and nausea who may benefit [from medical marijuana], but not from the glaucoma point of view.”